Systemic Therapy for Hepatocellular Carcinoma and Cholangiocarcinoma

被引：14

作者：

Chung, Vincent ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2015年 / 24卷 / 01期

关键词：

Hepatocellular carcinoma; Cholangiocarcinoma; Chemotherapy; Molecular targets; ADVANCED BILIARY CANCER; PHASE-II TRIAL; MILAN CRITERIA; TRACT CANCER; OPEN-LABEL; C-MET; GEMCITABINE; OXALIPLATIN; SORAFENIB; MULTICENTER;

D O I：

10.1016/j.soc.2014.09.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Understanding core signaling pathways in hepatic carcinogenesis has brought about a new era in the management of hepatocellular carcinoma. Sorafenib was the first molecular targeted therapy to be approved for advanced hepatocellular carcinoma and is the benchmark for all other therapies. Cytotoxic chemotherapy remains the mainstay treatment of advanced cholangiocarcinoma and there are no US Food and Drug Administration-approved molecular targeted therapies. If clinicians are able to minimize the toxicity of therapy by targeting the driving mechanism of cell proliferation, they will be able to significantly improve the survival and quality of life of patients.

引用

页码：187 / +

页数：13

共 24 条

[1]

American Cancer Society, 2014, CANC FACTS FIG 2014

[2]

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study [J].

Andre, T. ;

Reyes-Vidal, J. M. ;

Fartoux, L. ;

Ross, P. ;

Leslie, M. ;

Rosmorduc, O. ;

Clemens, M. R. ;

Louvet, C. ;

Perez, N. ;

Mehmud, F. ;

Scheithauer, W. .

BRITISH JOURNAL OF CANCER, 2008, 99 (06) :862-867

[3]

Cainap C, 2013, J CLIN ONCOL S34, V30

[4]

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Lin, Deng-Yn ;

Park, Joong-Won ;

Kudo, Masatoshi ;

Qin, Shukui ;

Chung, Hyun-Cheol ;

Song, Xiangqun ;

Xu, Jianming ;

Poggi, Guido ;

Omata, Masao ;

Lowenthal, Susan Pitman ;

Lanzalone, Silvana ;

Yang, Liqiang ;

Lechuga, Maria Jose ;

Raymond, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4067-+

[5]

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[6]

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: A preliminary report of the national cancer institute organ dysfunction working group [J].

Doroshow, JH ;

Synold, TW ;

Gandara, D ;

Mani, S ;

Remick, SC ;

Mulkerin, D ;

Hamilton, A ;

Sharma, S ;

Ramanathan, RK ;

Lenz, HJ ;

Graham, M ;

Longmate, J ;

Takimoto, CH ;

Ivy, P .

SEMINARS IN ONCOLOGY, 2003, 30 (04) :14-19

[7]

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study [J].

Johnson, Philip J. ;

Qin, Shukui ;

Park, Joong-Won ;

Poon, Ronnie T. P. ;

Raoul, Jean-Luc ;

Philip, Philip A. ;

Hsu, Chih-Hung ;

Hu, Tsung-Hui ;

Heo, Jeong ;

Xu, Jianming ;

Lu, Ligong ;

Chao, Yee ;

Boucher, Eveline ;

Han, Kwang-Hyub ;

Paik, Seung-Woon ;

Robles-Avina, Jorge ;

Kudo, Masatoshi ;

Yan, Lunan ;

Sobhonslidsuk, Abhasnee ;

Komov, Dmitry ;

Decaens, Thomas ;

Tak, Won-Young ;

Jeng, Long-Bin ;

Liu, David ;

Ezzeddine, Rana ;

Walters, Ian ;

Cheng, Ann-Lii .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) :3517-+

[8]

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial [J].

Knox, JJ ;

Hedley, D ;

Oza, A ;

Feld, R ;

Sin, LL ;

Chen, E ;

Nematollahi, M ;

Pond, GR ;

Zhang, J ;

Moore, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2332-2338

[9]

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study [J].

Lee, Jeeyun ;

Park, Se Hoon ;

Chang, Heung-Moon ;

Kim, Jun Suk ;

Choi, Hye Jin ;

Lee, Myung Ah ;

Jang, Joung Soon ;

Jeung, Hei Cheul ;

Kang, Jung Hun ;

Lee, Hyun Woo ;

Shin, Dong Bok ;

Kang, Hye Jin ;

Sun, Jong-Mu ;

Park, Joon Oh ;

Park, Young Suk ;

Kang, Won Ki ;

Lim, Ho Yeong .

LANCET ONCOLOGY, 2012, 13 (02) :181-188

[10]

Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria [J].

Lim, K-C ;

Chow, P. K-H ;

Allen, J. C. ;

Siddiqui, F. J. ;

Chan, E. S-Y ;

Tan, S-B .

BRITISH JOURNAL OF SURGERY, 2012, 99 (12) :1622-1629

← 1 2 3 →